Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Economic Burden of Spinal Muscular Atrophy from the Perspective of Public Health Institutions in Mexico

Speaker(s)

Diaz-Alvarez O1, Guzmán Vázquez S1, Frias Gasga AE1, Dominguez-Esquivel V1, Escobar Y1, Cortés-Sanabria L2, Soto H1
1Agencia Mexicana de Evaluación de Tecnologías Sanitarias AC, Iztapalapa, Mexico, 2Instituto Mexicano del Seguro Social, Guadalajara, JA, Mexico

Objectives: To carry out a study of the economic burden of the disease in patients with spinal muscular atrophy (SMA) type I, and both II & III, from the perspective of public health institutions in Mexico.

Methods: Two scenarios were considered, one with SMA type I and another including SMA type II & III. Direct medical costs associated with the management of patients with SMA was carried out. The costs were estimated based on the public data sources of the different health institutions in order to determine the cost per patient per year. The resources use was obtained through an exhaustive search in different databases. This information was validated through a Delphi panel with experts in the management of SMA in Mexico. A univariate deterministic sensitivity analysis was performed, modifying the incidence and prevalence of the disease.

Results: The annual cost of standard care for patients with SMA type I was $76,593.29, while for patients with SMA type II & III was $18,340.04. However, when the life expectancy of patients, the standard cost of treatments and the health budget are considered, a greater annual financial investment is observed for patients with SMA type II & III. In the sensitivity analysis, it is obtained that the incidence in SMA type II & III has the highest use of resources.

Conclusions: The annual cost per patient with SMA type I is 4 times higher than for SMA II & III. However, the financial impact is broader in patients with SMA type II & III since the accumulated target population is taken into account, thus increasing the investment year after year.

Code

EE378

Topic

Economic Evaluation

Disease

Musculoskeletal Disorders, Rare and Orphan Diseases